EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische Studie

Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)

Yuka Takahashi iD, Hiroshi Nomoto iD, Hiroki Yokoyama, Yoshinari Takano, So Nagai, Atsushi Tsuzuki, Kyu Yong Cho, Aika Miya iD, Hiraku Kameda, Jun Takeuchi, Shinji Taneda, Yoshio Kurihara und 4 weitere

Diabetes, Obesity and Metabolism · 2023

DOI: 10.1111/dom.14998 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Diabetes, Obesity and Metabolism, 2023. Verfasst von Yuka Takahashi und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 26 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aim

To investigate the effects of switching from liraglutide or dulaglutide to once‐weekly semaglutide on glycaemic control and treatment satisfaction in patients with type 2 diabetes. Materials and Methods In this multicentre, open‐labelled, prospective, randomized, parallel‐group comparison study, patients treated with liraglutide 0.9‐1.8 mg/day (plan A) or dulaglutide 0.75 mg/week (plan B) were either switched to semaglutide or continued current therapy. The primary endpoint was the mean change in glycated haemoglobin over 24 weeks. The secondary endpoints included the changes of Diabetes Treatment Satisfaction Questionnaire scores, body weight and metabolic indices.

Results

In total, 110 patients were enrolled, and 10 were excluded; therefore, 37 patients in plan A and 63 patients in plan B completed the study. Glycated haemoglobin levels were significantly reduced in the semaglutide group in both plans [plan A, 7.8% ± 1.0% to 7.8% ± 0.7% (liraglutide) vs. 7.9% ± 0.7% to 7.3% ± 0.7% (semaglutide), p < .01; plan B, 7.8% ± 1.0% to 7.9% ± 1.2% (dulaglutide) vs. 7.8% ± 0.8% to 7.1% ± 0.6% (semaglutide), p < .01]. Semaglutide also improved Diabetes Treatment Satisfaction Questionnaire scores in both groups (plan A, +0.1 vs. +8.3, p < .01; plan B, −1.2 vs. +3.5, p < .01). Switching from dulaglutide yielded greater reductions in body weight and improved metabolic parameters.

Conclusions

Once‐weekly semaglutide administration improved glycaemic control and treatment satisfaction after switching from liraglutide or dulaglutide. These results highlighted a useful treatment option for patients with metabolic abnormalities despite glucagon‐like receptor‐1 receptor agonist treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, Type 2HumansLiraglutideHypoglycemic AgentsGlycated HemoglobinProspective StudiesGlycemic ControlPatient SatisfactionGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsBody WeightPersonal SatisfactionSemaglutide

Stichwörter der Autor:innen

GLP-1 analogueclinical trialdulaglutideliraglutidesemaglutidetype 2 diabetes

Substanzen

LiraglutideHypoglycemic AgentsGlycated HemoglobinGlucagon-Like PeptidesImmunoglobulin Fc FragmentsRecombinant Fusion ProteinsSemaglutidedulaglutide

Autor:innen und Institutionen

  • Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan.
  • Jiyugaoka Medical Clinic, Obihiro, Japan.
  • Department of Diabetes and Endocrinology, Tonan Hospital, Sapporo, Japan.
  • Division of Diabetes and Endocrinology, Department of Medicine, Sapporo Medical Center, NTT East Corporation, Sapporo, Japan.
  • Clinical Research and Medical Innovation Center, Hokkaido University Hospital, Sapporo, Japan.
  • Sapporo Diabetes and Thyroid Clinic, Sapporo, Japan.

ORCID-Profile: Yuka Takahashi, Hiroshi Nomoto, Aika Miya, Hideaki Miyoshi

Zitieren

APA

Takahashi, Y., Nomoto, H., Yokoyama, H., Takano, Y., Nagai, S., Tsuzuki, A., Cho, K. Y., Miya, A., Kameda, H., Takeuchi, J., Taneda, S., Kurihara, Y., Atsumi, T., Nakamura, A., Miyoshi, H., & SWITCH-SEMA 1 study group (2023). Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study). Diabetes, Obesity and Metabolism. https://doi.org/10.1111/dom.14998

Vancouver

Takahashi Y, Nomoto H, Yokoyama H, Takano Y, Nagai S, Tsuzuki A, et al. Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study). Diabetes, Obesity and Metabolism. 2023. doi:10.1111/dom.14998

BibTeX
@article{Takahashi2023,
  author = {Takahashi, Yuka and Nomoto, Hiroshi and Yokoyama, Hiroki and Takano, Yoshinari and Nagai, So and Tsuzuki, Atsushi and Cho, Kyu Yong and Miya, Aika and Kameda, Hiraku and Takeuchi, Jun and Taneda, Shinji and Kurihara, Yoshio and Atsumi, Tatsuya and Nakamura, Akinobu and Miyoshi, Hideaki and SWITCH-SEMA 1 study group, SWITCH-SEMA 1 study group},
  title = {Improvement of glycaemic control and treatment satisfaction by switching from liraglutide or dulaglutide to subcutaneous semaglutide in patients with type 2 diabetes: A multicentre, prospective, randomized, open‐label, parallel‐group comparison study ( SWITCH‐SEMA 1 study)},
  journal = {Diabetes, Obesity and Metabolism},
  year = {2023},
  doi = {10.1111/dom.14998}
}
Kostenlos starten →